Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 21,025 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune System Disorders Clear all

Conditions: Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Choroid Plexus Neoplasm, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Primary Melanocytic Lesion of Meninges, Adult Supratentorial Primitive Neuroectodermal Tumor, Malignant Adult Intracranial Hemangiopericytoma, Metastatic Malignant Neoplasm in the Brain, Multiple Sclerosis, Recurrent Adult Brain Neoplasm
Interventions: Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadobutrol, Gadopentetate Dimeglumine; Procedure · Drug · Radiation
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Medication Adherence
Interventions: Adherence Counseling, General Health Counseling, Text Messages; Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Multiple Sclerosis, Relapsing-remitting
Interventions: Vitamin D3; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: San Francisco, California • Baltimore, Maryland

Conditions: Multiple Sclerosis
Interventions: 4.5 mg Naltrexone, Naltrexone; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 86 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Bortezomib, Dexamethasone, Autologous Stem Cell Transplant; Drug · Procedure
Lead sponsor: Paul Richardson, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 46
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 37 more

Conditions: Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Relapsed and/or Refractory Lymphoma, Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Double-hit Lymphoma (DHL), Triple-hit Lymphoma (THL), Double-expressor Lymphoma (DEL), High-grade B-cell Lymphoma (HGBL)
Interventions: fimepinostat, Rituximab, venetoclax; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 11
States / cities: Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 8 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Observation of Ocrelizumab as Treatment in RRMS Patients; Other
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
Interventions: Ciclesonide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM, T-cell NHL
Interventions: CB-839, CB-839 and low dose dexamethasone, CB-839, pomalidomide, and low dose dexamethasone; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Scottsdale, Arizona • Denver, Colorado • Atlanta, Georgia + 4 more

Conditions: HIV Positive
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 1,150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Meningitis, Encephalitis, Guillain-Barré, Subarachnoid Hemorrhage, Intracranial Neoplasm, Intracranial CNS Disorder
Interventions: LPat Device; Device
Lead sponsor: Spartanburg Regional Healthcare System; Other
Eligibility: 12 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Multiple Sclerosis
Interventions: Narrow pulse, Wide pulse; Device
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions: Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide; Drug
Lead sponsor: Leaf Vertical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Lymphoma
Interventions: Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: dnaJ peptide, None-placebo; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 8
States / cities: Tucson, Arizona • Orange, California • Palo Alto, California + 5 more

Conditions: Arthritis, Rheumatoid
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: Not listed
Enrollment: 1,712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions: SB-509, Saline; Drug · Other
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more

Conditions: Lymphoma, Relapsed/Refractory T-cell Lymphomas
Interventions: Romidepsin, Bortezomib, duvelisib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 11
States / cities: Stanford, California • Boston, Massachusetts • St Louis, Missouri + 7 more

Conditions: Hodgkin Lymphoma
Interventions: Brentuximab Vedotin, Doxorubicin, Vincristine, Rituximab; Drug
Lead sponsor: Mitchell Cairo; Other
Eligibility: 1 Year to 29 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Type 1 Diabetes Mellitus
Interventions: INGAP Peptide, Placebo; Drug
Lead sponsor: Exsulin Corporation; Industry
Eligibility: 19 Years to 60 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Seasonal, Asthma
Interventions: Clinical Center Reference Endotoxin (CCRE); Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections, Syphilis
Interventions: Cepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: VRC07-523LS, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: Graft vs Host Disease, Sjogren's Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

Nurse Delivered Cell Phone Adherence Intervention (Pick It UP)

Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health

A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Thinking and Memory Problems in People With HIV

The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat)

Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

dnaJ Peptide for Relieving Rheumatoid Arthritis

A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Brentuximab for Newly Diagnosed Hodgkin Disease

Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults

Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells